Frontline Shift for Severe Aplastic Anemia After Eltrombopag FDA Approval

Dr. Deol on the FDA Approval of Eltrombopag in Severe Aplastic AnemiaПодробнее

Exciting new immunosuppressive therapy treatment for aplastic anaemiaПодробнее

Dr. Young on Eltrombopag Added to Immunosuppression for Patients With Aplastic AnemiaПодробнее

Unmet Needs in Severe Aplastic Anemia and Exciting Ongoing DevelopmentsПодробнее

Late-Breaking Abstract: Eltrombopag Improves Response in Severe Aplastic AnemiaПодробнее

The Role of Supportive Care in Severe Aplastic AnemiaПодробнее

RACE: evaluating eltrombopag in severe aplastic anemiaПодробнее

Eltrombopag increases hematologic response in patients with treatment-naïve severe aplastic anemiaПодробнее

ASH 2016: Aplastic Anemia Research UpdateПодробнее

History of Aplastic Anemia - Past, Present and FutureПодробнее

Relapse Prevention in Aplastic AnemiaПодробнее

Can children with aplastic anaemia get access to eltrombopag?Подробнее

Upcoming SAA research: cyclosporine and eltrombopagПодробнее

Advances in transplantation and drug treatments for idiopathic aplastic anemiaПодробнее

Eltrombopag Trial and Treatment DiscontinuationПодробнее

Eltrombopag in a nutshell - Promacta (Pronunciation - Indication - US Black Box)Подробнее

Conversations with Innovators: Neal Young, MDПодробнее

Recorded Live from Jacksonville! Aplastic Anemia Updates for PatientsПодробнее

Eltrombopag Approval, Cabozantinib Breakthrough Designation, Pembrolizumab Priority Review, and MoreПодробнее